Navigation Links
12-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system)

clinical trials. Those children not optimized on DAYTRANA from the previous trials entered a four- week stepwise DAYTRANA dose-optimization phase. All children then entered an 11-month DAYTRANA dose maintenance phase. DAYTRANA was applied each morning to the hip area and worn for approximately nine hours daily. During the dose- optimization phase, titration to a higher dose was permitted after a minimum of three days. Tapering to a lower dose was permitted throughout the dose optimization period and dose adjustments were also permitted during the dose maintenance period.

All of the children in this open-label, flexible-dose trial participated in one of four trials in which the children previously received DAYTRANA, OROS methylphenidate or a placebo. All of the children previously used DAYTRANA for at least a minimum of three days and a maximum of 37 months. While this study evaluated the safety and effectiveness of DAYTRANA for up to 12 months, DAYTRANA has not been studied versus placebo for longer than 7 weeks. Physicians, who prescribe DAYTRANA for long-term use, should periodically re- evaluate patients to assess the usefulness of DAYTRANA for the individual patient.

Children were diagnosed with ADHD using DSM-IV-TR(R) criteria. Researchers assessed safety and tolerability, through physical exams, skin evaluations, laboratory tests, and monitoring of vital signs, including ECGs throughout the study.

The ADHD-RS-IV assesses 18 individual symptoms of ADHD as defined by the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR(R)), a publication of the American Psychiatric Association.

Of the 327 children enrolled, 157 completed the study. Investigators used data from the intent-to-treat population (324 children) for the efficacy evaluations. Of the safety population (326 children) 7 percent withdrew due to skin irritation at the patch application site, and 9 percent withdrew due to adverse even
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Medivation to Host Conference Call to Discuss Top-Line 12-Month Results From Dimebon Alzheimers Disease Study
2. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
3. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
4. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
11. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
Post Your Comments:
(Date:7/29/2014)... Colo. , July 29, 2014 New ... (MARC) which could allow physicians to see and assess ... hold promise, according to study authors who released their ... 11 th Annual Meeting in Colorado ... to advance the field of neurointervention, a specialty that ...
(Date:7/29/2014)... 2014 /PRNewswire-iReach/ -- MHG Medical Management Services, a ... Medical Equipment and X-ray Annual Inspection & ... to the cruise industry,s unique requirements.  MHG Medical,s ... propose that they should develop a new service. ... intended to create standardized processes and raise standards, ...
(Date:7/29/2014)... July 29, 2014  Neurocrine Biosciences, Inc. (Nasdaq: ... report its second quarter 2014 financial results after the ... will then host a live conference call and webcast ... update Thursday morning, August 7, 2014 at 8:00 a.m. ... can access the live conference call by dialing 866-952-1907 ...
Breaking Medicine Technology:New Technology May Improve Visualization Of The Brain During Stroke Treatment 2New Technology May Improve Visualization Of The Brain During Stroke Treatment 3MHG Medical Management Services Aims to Change Cruise Industry Standard With New Equipment Maintenance Program 2Neurocrine Biosciences Announces Conference Call And Webcast To Report Second Quarter 2014 Financial Results 2
... NanoBio Corporation,announced today that it has seen ... 2 study of NB-002, a topical lotion for ... results clearly,justify completing the study, according to NanoBio ... grow out a clear nail after,successfully treating the ...
... March 20 PLC Systems Inc.,(Amex: PLC ... approval from,the U.S. Food and Drug Administration (FDA) ... study the effectiveness of the Company,s RenalGuard,Therapy(TM) and ... Mark R. Tauscher, President and Chief Executive ...
Cached Medicine Technology:NanoBio Corporation Completes Interim Analysis of Phase 2 Clinical Trial in Onychomycosis 2PLC Systems Receives FDA Approval to Commence Pivotal Study Of RenalGuard(TM) In the U.S. 2PLC Systems Receives FDA Approval to Commence Pivotal Study Of RenalGuard(TM) In the U.S. 3PLC Systems Receives FDA Approval to Commence Pivotal Study Of RenalGuard(TM) In the U.S. 4
(Date:7/30/2014)... According to the Nasal Polyps Treatment Miracle book review ... teaches people how to cure their nasal polyps ... the horrible truth about conventional treatments for nasal polyps. ... people will learn how to prevent symptoms related to ... , Nasal Polyps Treatment Miracle, as it is reviewed now ...
(Date:7/30/2014)... San Francisco, CA (PRWEB) July 30, 2014 ... charge capture and physician communication, launched an Observation ... performed in the hospital. pMD’s cardiology customers are ... and optimize revenue for their test interpretations for ... provider interprets tests in the hospital, the cardiology ...
(Date:7/29/2014)... Paul Mata, CEO of ‘Create Indestructible Wealth,’ ... 30 Days” E-book. The e-book includes a myriad of fast ... cash. Examples include downloading and utilizing specific phone apps ... people monetize the assets they didn't know they had like ... find in their garage. , After reading the e-book, ...
(Date:7/29/2014)... Ireland (PRWEB) July 30, 2014 Dignity ... the successful completion of a Phase I trial with ... (DGLA). , This study was a randomized, placebo-controlled, double-blind, ... assess the safety, pharmacokinetics and effect of food on ... the benign safety profile of DGLA following both single ...
(Date:7/29/2014)... (EA) a form of acupuncture where a ... acupuncture needles produces significant improvements in fatigue, ... weeks for early stage breast cancer patients experiencing ... inhibitors (AIs) to treat breast cancer. The results ... led by researchers at the Perelman School of ...
Breaking Medicine News(10 mins):Health News:Nasal Polyps Treatment Miracle Book Review Exposes Manuel Richards' Guide For Treating Nasal Polyps – Vkool.com 2Health News:Nasal Polyps Treatment Miracle Book Review Exposes Manuel Richards' Guide For Treating Nasal Polyps – Vkool.com 3Health News:pMD Automates Cardiology Charge Capture: Low-Reimbursement Services Become Profitable 2Health News:pMD Automates Cardiology Charge Capture: Low-Reimbursement Services Become Profitable 3Health News:Create Indestructible Wealth Launches Innovative E-Book: “Realistic Ways to Make More Money in 30 Days” 2Health News:DS107G-01 – Successful Completion of Phase I Oral DGLA Clinical Trial 2Health News:Acupuncture improves quality of life for breast cancer patients using aromatase inhibitors 2Health News:Acupuncture improves quality of life for breast cancer patients using aromatase inhibitors 3
... markets Aricept with Pfizer Inc. Aricept is already approved in ... but at present it was being tested in patients with ... Alzheimer's disease. ,But the shocking results show that ... clinical trial held at Japan's Eisai Co. ,There ...
... Dr Charles Reynolds at the University of Pittsburgh which was ... , The study’s main aim was to analyze the effect ... It is one of the longest studies ever in ... for longer periods, perhaps even for life, in patients who ...
... increasing number of addicts. Health authorities are warning of the ... with the consequences. ,Statistics show that about one ... Vincent's Hospital has recorded a five-fold increase in patients suffering ... in Australia. , The reason being that ice ...
... condition that affects millions of people. Scientists at the University ... leading to eczema and asthma. ,This gene produces ... outermost layers of the skin. It prevents bacteria and viruses ... to prevent the skin from drying. Reduction or absence of ...
... soon going to have more up market looking// medical stores ... supply free medicines to the patients., ,Apparently the ... ‘swanky medical stores’. These will be located at the entrance ... (BPL)’ card holders..., ,Mr Ashok said that these ...
... approval to formation of a Health Task Force for India.//, ... in the health sector in India which includes doctors, nurses ... commission on macroeconomics and health in its report,” a statement ... were also growing opportunities with India emerging as a major ...
Cached Medicine News:Health News:Drugs Are Effective In Treating Depression and Preventing Recurrence 2Health News:Gene That Causes Dry Skin, Identified 2
... utilizes allele-specific primer combinations in the PCR ... that only primers whose sequence is completely ... converted by the polymerase into PCR products. ... product. Using the Biotest SSP Kit Systems, ...
... The freezer is constructed with built-in bags ... the plasma bags are placed without contacting the ... and heavy inserts. This device ensures easy handling ... immersed plasma bags so that the relatively hot ...
Helmer offers Plasma Storage Freezer lines, the i.Series ipf 125-8. It is Designed to complement Blood Bank Refrigerators, it freezers offer outstanding features, including programmable defrost tim...
Plasma Blast Chest Freezer -50C - 8098/8091 maintains a -50C (-58F) temperature to rapidly freeze single donor, apheresed, and fresh frozen plasma. Rapid freezing also preserves Factor VIII. Full loa...
Medicine Products: